BlackRock Amends TG Therapeutics Stake, Signals Position Update
Ticker: TGTX · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1001316
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock updated its TG Therapeutics stake, watch for market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of TG Therapeutics, Inc. common stock as of December 31, 2023. This amendment, number 4, updates their previous disclosures regarding their stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
Large institutional investors like BlackRock often conduct extensive due diligence; their updated holdings can be seen as a vote of confidence or concern, potentially impacting stock price and investor sentiment.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of institutional ownership and does not inherently signal high risk, but rather transparency.
Analyst Insight
Investors should note BlackRock's continued involvement with TG Therapeutics, but without specific share count changes in this excerpt, it's difficult to gauge a strong bullish or bearish signal. Further analysis of the full filing for share count changes would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- TG Therapeutics, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring this filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 4 (number) — the specific amendment number for this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' (the entity filing the report) is BlackRock Inc., with a Central Index Key (CIK) of 0001364742.
What company's securities are the subject of this filing?
The subject company is TG Therapeutics, Inc., with a Central Index Key (CIK) of 0001001316, and the securities are its Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Which rule under the Securities Exchange Act of 1934 is designated for this filing?
This Schedule is filed pursuant to Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding TG THERAPEUTICS, INC. (TGTX).